The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
French biopharma company Inventiva saw its US traded shares jump 11.1% to $4.19 yesterday, after it announced a deal with Japan-based Hepalys Pharma, a company incubated by Catalys Pacific. 22 September 2023
The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) alongside lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use in England and Wales. 22 September 2023
Australian allogenic cellular medicines developer Mesoblast closed down 3.4% at A$1.265 yesterday, after it provided an update on the path to approval for its lead-product candidate Ryoncil. 22 September 2023
The US Court of Appeals for the Federal Circuit has quashed an appeal from the Takeda unit Baxalta in relation to Roche’s hemophilia treatment Hemlibra (emicizumab). 22 September 2023
Shares of Travere Therapeutics plunged more than 40% to $7.65 yesterday after it released top-line two-year confirmatory secondary endpoint results from the pivotal head-to-head Phase III PROTECT study of Filspari (sparsentan) in IgA nephropathy (IgAN), which narrowly missed eGFR total slope endpoint compare to irbesartan. 22 September 2023
It may feel like groundhog day for the beleaguered backers of a novel drug-device product developed by biotech unicorn Intarcia Therapeutics. 22 September 2023
The Institute of Cancer Research in London and German science and technology company Merck KGaA have renewed their strategic alliance in the discovery and development of new cancer drugs. 22 September 2023
Accent Therapeutics, a US biopharma company developing a new class of small molecule precision cancer therapies, has announced three appointments in one at what is a pivotal time for the firm. 21 September 2023
California, USA-based clinical-stage biopharmaceutical company 89bioe edged up 2% to $15.37 in morning trading, after it revealed that the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to pegozafermin in patients with non-alcoholic steatohepatitis (NASH). 21 September 2023
A new collaboration will see Californian biotech Kezar Life Sciences and China’s Everest Medicines working together on an immunoproteasome blocker, zetomipzomib. 21 September 2023
Dutch firm Anavo Therapeutics, which claims to be the first company to systematically drug phosphatases, has named Shaun McNulty its chief scientific officer (CSO). 21 September 2023
Monaco-based hormonal medicines supplier Besins Healthcare yesterday opened a new state-of-the-art hormone replacement therapy (HRT) production facility in Muel, near Zaragoza, Spain, to help meet the increased demand for HRT products for women across the UK, Europe, and the world. 21 September 2023
Cambridge, UK-based biotech Maxion Therapeutics has announced the appointment of senior industry leader Eva-Lotta Allan as chairwoman of its board of directors. 21 September 2023
Research from a medical testing company, London Medical Laboratory, finds that there is a “critical medication shortage” facing many diabetics in the UK. 21 September 2023
Florida-based central nervous system (CNS) specialist Relmada Therapeutics has announced positive results from a late-stage trial of REL-1017. 21 September 2023
Following a favorable recommendation form the European Medicines Agency’s advisory committee on July, the European Commission (EC) has now granted marketing authorization in the European Union (EU) for Indian drugmaker Biocon’s Yesafili, a biosimilar of Eylea (aflibercept). 21 September 2023